324 related articles for article (PubMed ID: 19432851)
1. Comparison of intravenous iron sucrose versus low-molecular-weight iron dextran in chronic kidney disease.
Sinha S; Chiu DY; Peebles G; Kolakkat S; Lamerton E; Fenwick S; Kalra PA
J Ren Care; 2009 Jun; 35(2):67-73. PubMed ID: 19432851
[TBL] [Abstract][Full Text] [Related]
2. Is there a difference between the allergic potencies of the iron sucrose and low molecular weight iron dextran?
Sav T; Tokgoz B; Sipahioglu MH; Deveci M; Sari I; Oymak O; Utas C
Ren Fail; 2007; 29(4):423-6. PubMed ID: 17497463
[TBL] [Abstract][Full Text] [Related]
3. [Parenteral iron therapy: problems and possible solutions].
Hoigné R; Breymann C; Künzi UP; Brunner F
Schweiz Med Wochenschr; 1998 Apr; 128(14):528-35. PubMed ID: 9592894
[TBL] [Abstract][Full Text] [Related]
4. Improving efficiency and value in health care. Intravenous iron management for anaemia associated with chronic kidney disease: linking treatment to an outpatient clinic, optimizing service provision and patient choice.
Bhandari S; Naudeer S
J Eval Clin Pract; 2008 Dec; 14(6):996-1001. PubMed ID: 18785894
[TBL] [Abstract][Full Text] [Related]
5. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease--a randomized, controlled, open-label, multicenter study.
Schröder O; Mickisch O; Seidler U; de Weerth A; Dignass AU; Herfarth H; Reinshagen M; Schreiber S; Junge U; Schrott M; Stein J
Am J Gastroenterol; 2005 Nov; 100(11):2503-9. PubMed ID: 16279906
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of total dose infusion of iron dextran in iron deficiency anaemia.
Reddy CM; Kathula SK; Ali SA; Bekal R; Walsh M
Int J Clin Pract; 2008 Mar; 62(3):413-5. PubMed ID: 18005041
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trial.
Van Wyck DB; Cavallo G; Spinowitz BS; Adhikarla R; Gagnon S; Charytan C; Levin N
Am J Kidney Dis; 2000 Jul; 36(1):88-97. PubMed ID: 10873877
[TBL] [Abstract][Full Text] [Related]
8. The safety of intravenous iron dextran (Dexferrum) during hemodialysis in patients with end stage renal disease.
Hood SA; O'Brien M; Higgins R
Nephrol Nurs J; 2000 Feb; 27(1):41-2. PubMed ID: 10852689
[TBL] [Abstract][Full Text] [Related]
9. Acute injury with intravenous iron and concerns regarding long-term safety.
Bishu K; Agarwal R
Clin J Am Soc Nephrol; 2006 Sep; 1 Suppl 1():S19-23. PubMed ID: 17699372
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of total dose infusion of low molecular weight iron dextran in the treatment of iron deficiency anemia during pregnancy.
Ayub R; Tariq N; Adil MM; Iqbal M; Junaid A; Jaferry T
J Coll Physicians Surg Pak; 2008 Jul; 18(7):424-7. PubMed ID: 18760066
[TBL] [Abstract][Full Text] [Related]
11. Slow intravenous iron administration does not aggravate oxidative stress and inflammatory biomarkers during hemodialysis: a comparative study between iron sucrose and iron dextran.
Malindretos P; Sarafidis PA; Rudenco I; Raptis V; Makedou K; Makedou A; Grekas DM
Am J Nephrol; 2007; 27(6):572-9. PubMed ID: 17804904
[TBL] [Abstract][Full Text] [Related]
12. The efficacy of a single dose of intravenous ferric carboxymaltose (Ferinject) on anaemia in a pre-dialysis population of chronic kidney disease patients.
Tagboto S; Cropper L; Turner J; Pugh-Clarke K
J Ren Care; 2009 Mar; 35(1):18-23. PubMed ID: 19200274
[TBL] [Abstract][Full Text] [Related]
13. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
Li H; Wang SX
Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of iron sucrose for iron deficiency in patients with dialysis-associated anemia: North American clinical trial.
Charytan C; Levin N; Al-Saloum M; Hafeez T; Gagnon S; Van Wyck DB
Am J Kidney Dis; 2001 Feb; 37(2):300-7. PubMed ID: 11157370
[TBL] [Abstract][Full Text] [Related]
15. Intravenous iron dextran treatment in predialysis patients with chronic renal failure.
Dahdah K; Patrie JT; Bolton WK
Am J Kidney Dis; 2000 Oct; 36(4):775-82. PubMed ID: 11007680
[TBL] [Abstract][Full Text] [Related]
16. Intravenous versus oral iron therapy for postpartum anaemia.
Bhandal N; Russell R
BJOG; 2006 Nov; 113(11):1248-52. PubMed ID: 17004982
[TBL] [Abstract][Full Text] [Related]
17. Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease.
Auerbach M; Al Talib K
Kidney Int; 2008 Mar; 73(5):528-30. PubMed ID: 18274543
[TBL] [Abstract][Full Text] [Related]
18. Addressing patient concerns about intravenous iron therapy.
Robbins KC
Nephrol Nurs J; 2003 Apr; 30(2):220-4, 258. PubMed ID: 12737000
[TBL] [Abstract][Full Text] [Related]
19. A randomized trial of three iron dextran infusion methods for anemia in EPO-treated dialysis patients.
Auerbach M; Winchester J; Wahab A; Richards K; McGinley M; Hall F; Anderson J; Briefel G
Am J Kidney Dis; 1998 Jan; 31(1):81-6. PubMed ID: 9428456
[TBL] [Abstract][Full Text] [Related]
20. [Parenteral iron replacement].
Cynke E
Praxis (Bern 1994); 1997 May; 86(20):835-6. PubMed ID: 9312810
[No Abstract] [Full Text] [Related]
[Next] [New Search]
